Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brad Kahl

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Hematological Oncology|June 9, 2021
High-risk follicular lymphoma: Treatment optionsBrad Kahl
Best Practice & Research. Clinical Haematology|February 18, 2018
Indolent lymphomasBrad Kahl
Hematology. American Society of Hematology. Education Program|December 13, 2012
Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?Brad Kahl
Seminars in Hematology|April 3, 2008
Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphomaBrad Kahl
Critical Reviews in Oncology/Hematology|December 21, 2010
Mantle cell lymphoma: the promise of new treatment optionsAndre Goy, Brad Kahl
Targeted Oncology|March 10, 2018
Targeting BCL-2 in Hematologic MalignanciesNadia Khan, Brad Kahl
Hematology. American Society of Hematology. Education Program|December 17, 2008
Marginal zone lymphomas: management of nodal, splenic, and MALT NHLBrad Kahl, David Yang
Therapeutic Advances in Hematology|August 17, 2017
Current and emerging treatment options for mantle cell lymphomaBita Fakhri, Brad Kahl
Clinical Lymphoma, Myeloma & Leukemia|June 2, 2023
SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell LymphomaDilan Patel, Brad Kahl
Best Practice & Research. Clinical Haematology|September 15, 2018
Evolving treatment strategies in mantle cell lymphomaNatasha Catherine Edwin, Brad Kahl
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Hematological Oncology|June 9, 2021
High-risk follicular lymphoma: Treatment optionsBrad Kahl
Best Practice & Research. Clinical Haematology|February 18, 2018
Indolent lymphomasBrad Kahl
Hematology. American Society of Hematology. Education Program|December 13, 2012
Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?Brad Kahl
Seminars in Hematology|April 3, 2008
Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphomaBrad Kahl
Critical Reviews in Oncology/Hematology|December 21, 2010
Mantle cell lymphoma: the promise of new treatment optionsAndre Goy, Brad Kahl
Targeted Oncology|March 10, 2018
Targeting BCL-2 in Hematologic MalignanciesNadia Khan, Brad Kahl
Hematology. American Society of Hematology. Education Program|December 17, 2008
Marginal zone lymphomas: management of nodal, splenic, and MALT NHLBrad Kahl, David Yang
Therapeutic Advances in Hematology|August 17, 2017
Current and emerging treatment options for mantle cell lymphomaBita Fakhri, Brad Kahl
Clinical Lymphoma, Myeloma & Leukemia|June 2, 2023
SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell LymphomaDilan Patel, Brad Kahl
Best Practice & Research. Clinical Haematology|September 15, 2018
Evolving treatment strategies in mantle cell lymphomaNatasha Catherine Edwin, Brad Kahl
Pageof 7